Tara Austraat-Churik, Partner, Blue Matter.
Life sciences consulting firm appoints Partner Tara Austraat-Churik to head a new practice aimed at helping clients navigate increasing complexity in drug development, from AI integration to clinical trial management.
Blue Matter, a consulting firm focused on the life sciences industry, has established a new practice area dedicated to biopharmaceutical Research & Development (R&D). The new division is led by Partner Tara Austraat-Churik, who joined the firm in September 2025.
The move comes as biopharma companies face a host of challenges in bringing new therapies to market. According to Austraat-Churik, the new practice is designed to help clients manage this environment. "R&D organizations face an extremely complex world right now," she said. "Artificial intelligence is transforming all aspects of R&D, pressure to keep pipelines full is driving companies to seek new sources of innovation, and clinical trial complexity is rising."
Austraat-Churik brings over two decades of experience in life sciences consulting to the role. Before joining Blue Matter, she was a Managing Director in the R&D, Health, Science and Wellness practice at EY. Her career also includes roles at Booz Allen Hamilton, Navitas, WPP and IBM, with expertise in strategy, operating model design and process optimization.
The new practice will offer services that span the development lifecycle, from innovation and discovery through clinical development, regulatory strategy and post-market surveillance. "We help ensure that clients have the right organization, capabilities, processes, and technologies to excel across those areas," Austraat-Churik noted.
According to Managing Partner Ashwin Dandekar, the expansion into R&D consulting is a strategic move to better connect the development and commercialization phases for clients. "Blue Matter does so much work to prepare development-stage companies and assets for commercialization that it made tremendous sense to help optimize the development process, too," Dandekar stated. "Development and commercial strategy should, after all, be tightly integrated and neither should exist in a silo." This approach of integrating development and commercial strategy reflects a broader trend within the consulting industry to provide more holistic, end-to-end support for clients' product lifecycles.
SOURCE: Blue Matter
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.